Phase 3 CDKL5 deficiency disorder (CDD) results: UCB shares 21 scientific abstracts, including the presentation of positive primary efficacy and safety results from a phase 3 study of FINTEPLA®...

CIMG Inc. ("CIMG" or the "Company") (Nasdaq: IMG), a business group specializing in digital health and sales development, which utilizes technology and marketing to enhance its business partners'...

Powerfleet, Inc. (Nasdaq: AIOT) today announced that management is scheduled to attend the following December 2025 investor conferences to discuss Powerfleet's scaled AIoT platform, strong...

The MPN Research Foundation, a respected and global influential member of the MPN landscape, has two abstracts accepted for the 67th American Society of Hematology (ASH) Annual Meeting and...

Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies...